AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 161 min read$CTSO

Capponi Vincent purchased $13K of CTSO

Capponi Vincent (President and COO) purchased 2,073 shares of Cytosorbents Corp (CTSO) at an average of $6.05 ($5.90–$6.07) across 2 trades on 2026-09-14.

Original reporting
SEC EDGAR · Capponi Vincent
Published Sep 16, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CTSO
Neutral
low confidence
Mentioned
$CTSO
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CTSONeutralLow
01

Why it matters

The transaction is minor and unlikely to affect CTSO's stock price materially.

02

Market read

Small insider purchase with limited trading relevance.

03

What to watch

Potential upcoming product approvals or contract wins not disclosed.

Relevance 4/10Novelty 4/10Timing: filed Sep 16, 2026 (post‑market)

Background

Form 4 filings disclose insider trades; this is the first public report of this transaction.

Company-level read

Ticker impact

$CTSONeutralLow confidence
Context

President and COO Vincent Capponi bought 2,073 shares for $12.5K, increasing his stake to 40,387 shares.

Expected impact

minimal to none

Evidence & confidence

Purchase amount is under $20K and represents a tiny fraction of float; unlikely to move market.

Market effects

Sector

None; Cytosorbents operates in niche medical device space.

Regional

None; company is US‑listed with limited regional exposure.

Global

None

Counterpoint

What could challenge this read

Insider buy could be a subtle confidence signal despite small size.

Key entities

  • Company
    Cytosorbents Corp

    US‑listed medical device company (ticker CTSO).

  • Insider
    Vincent Capponi

    President and COO of Cytosorbents.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CTSO insider trading history →

Related articles

AUG 14
$CTSOMed

Cytosorbents (CTSO) Q2 2026 Earnings Call Transcript

Cytosorbents (CTSO) reported Q2 2026 revenue of $9.6 million, flat vs. the prior year and up 9% sequentially, with 73% gross margin. Adjusted EBITDA loss was $1.6 million, a 38% improvement. Net loss was $4.4 million. Management discussed FDA strategy for DrugSorb-ATR after a de novo denial, and progress on HemoDefend-BGA. Cash was $5.9 million.

fool.com6 min
JUN 2
$CTSOMedAI 9/10

Cytosorbents (CTSO) Q1 2026 Earnings Transcript

Cytosorbents (CTSO) reported Q1 2026 revenue of $8.9 million, up 2% YoY, with direct international markets (excluding Germany) up 13% while Germany declined. Gross margin fell to 69% from 71%. Adjusted EBITDA loss narrowed to $2.2 million (vs. $2.7 million), as operating expenses dropped to $9.2 million. Net loss was $5.1 million ($0.08/share). FDA said DrugSorb-ATR needs additional non-clinical data and real-world evidence for a de novo submission, likely pushing timing to late 2026/early 2027.

fool.com6 min